These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
536 related articles for article (PubMed ID: 22894854)
1. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854 [TBL] [Abstract][Full Text] [Related]
2. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
5. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679 [TBL] [Abstract][Full Text] [Related]
6. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294 [TBL] [Abstract][Full Text] [Related]
7. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
8. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486 [TBL] [Abstract][Full Text] [Related]
10. Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Strati A; Kasimir-Bauer S; Markou A; Parisi C; Lianidou ES Breast Cancer Res; 2013 Mar; 15(2):R20. PubMed ID: 23497487 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T; Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
13. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322 [TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T; ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105 [TBL] [Abstract][Full Text] [Related]
16. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222 [TBL] [Abstract][Full Text] [Related]
17. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347 [TBL] [Abstract][Full Text] [Related]
18. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662 [TBL] [Abstract][Full Text] [Related]
20. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]